TRex Bio priced 8,333,334 shares at $14.00 each, for $116,666,676 before underwriting fees. Eli Lilly, which paid the company a $55.0 million upfront in 2023, has indicated interest in buying shares, but the indication is not binding.
TRex Bio filed for a Nasdaq IPO on September 18, 2026. Eli Lilly, which signed a research collaboration with the company in 2023, has indicated interest in buying shares, but the indication is not binding and the price range and share count are still blank.
Questions about TRex Bio
When did TRex Bio go public?
Our latest story on this, dated Oct 9, 2026: "TRex Bio prices IPO of 8,333,334 shares at $14.00 each". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of TRex Bio?
TRex Bio, Inc. trades under the ticker TRXB on NASDAQ.
Where is TRex Bio listed?
TRex Bio, Inc. is listed on NASDAQ.
What is the SEC CIK of TRex Bio?
The SEC Central Index Key (CIK) for TRex Bio, Inc. is 2139097. Its filings are on SEC EDGAR.
Which country or territory is TRex Bio listed under?
Our directory records TRex Bio, Inc. under United States.
What does TRex Bio do?
Our directory classifies TRex Bio, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of TRex Bio?
The ISIN recorded for TRex Bio, Inc. is US89531N1000.
Does aibio.space cover TRex Bio?
aibio.space lists TRex Bio, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is TRex Bio incorporated?
SEC records list its state or country of incorporation as DE.
What is the latest TRex Bio (TRXB) stock news?
Our latest story on TRex Bio, dated Oct 9, 2026: "TRex Bio prices IPO of 8,333,334 shares at $14.00 each". TRex Bio priced 8,333,334 shares at $14.00 each, for $116,666,676 before underwriting fees. Eli Lilly, which paid the company a $55.0 million upfront in 2023, has indicated interest in buying shares, but the indication is not binding. Source.
What is TRex Bio's latest stock offering or financing news?
Our latest financing story, dated Oct 9, 2026: "TRex Bio prices IPO of 8,333,334 shares at $14.00 each". TRex Bio priced 8,333,334 shares at $14.00 each, for $116,666,676 before underwriting fees. Eli Lilly, which paid the company a $55.0 million upfront in 2023, has indicated interest in buying shares, but the indication is not binding. Source.
Who were the underwriters or placement agents on TRex Bio's offering?
From our story: J.P. Morgan, Evercore ISI, Cantor, Stifel and Wedbush PacGrow are named on the cover as the underwriters. Source.
How long will TRex Bio's cash last?
From our story of Oct 9, 2026: The company says its year-end cash plus those proceeds will fund operations for at least twelve months from the date the financial statements were issued. Source.
How much cash does TRex Bio have?
From our story of Oct 9, 2026: At December 31, 2025, cash, cash equivalents and marketable securities totaled $67.7 million, and the accumulated deficit was $94.3 million. Source.
Is TRex Bio a smaller reporting company?
SEC records list TRex Bio, Inc.'s filer category as: <br>Emerging growth company.
Investor discussion: TRex Bio
Members talk about TRex Bio (TRXB). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at TRex Bio, newest first. Each line links the filing it comes from.
Financings
Filed a final prospectus for a securities offering. SEC Form 424B4. Source
Financings
Filed a registration statement for a share offering. SEC Form S-1. Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:TRXB on TradingView.
SEC filings and registration
SEC name
TRex Bio, Inc.
CIK
2139097
Industry (SIC)
Biological Products, (No Diagnostic Substances) (2836)
US tickers
TRXB (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
<br>Emerging growth company
Business address
C/O TREX BIO, INC., SOUTH SAN FRANCISCO, CA
Phone
(650) 567-5582
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
TRex Bio, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker TRXB, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio